HomeCompareEFRMF vs PFE

EFRMF vs PFE: Dividend Comparison 2026

EFRMF yields 6451.61% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EFRMF wins by $746046519283998.88M in total portfolio value
10 years
EFRMF
EFRMF
● Live price
6451.61%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$746046519283998.88M
Annual income
$723,972,000,481,503,000,000.00
Full EFRMF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — EFRMF vs PFE

📍 EFRMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEFRMFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EFRMF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EFRMF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFRMF
Annual income on $10K today (after 15% tax)
$548,387.10/yr
After 10yr DRIP, annual income (after tax)
$615,376,200,409,277,500,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, EFRMF beats the other by $615,376,200,409,277,500,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFRMF + PFE for your $10,000?

EFRMF: 50%PFE: 50%
100% PFE50/50100% EFRMF
Portfolio after 10yr
$373023259641999.44M
Annual income
$361,986,000,240,751,500,000.00/yr
Blended yield
97.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

EFRMF
No analyst data
Altman Z
-10.4
Piotroski
1/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFRMF buys
0
PFE buys
0
No recent congressional trades found for EFRMF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEFRMFPFE
Forward yield6451.61%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$746046519283998.88M$49.6K
Annual income after 10y$723,972,000,481,503,000,000.00$26,258.71
Total dividends collected$744564070034128.50M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EFRMF vs PFE ($10,000, DRIP)

YearEFRMF PortfolioEFRMF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$655,861$645,161.29$9,153$693.39+$646.7KEFRMF
2$40,247,222$39,545,450.12$8,593$849.25+$40.24MEFRMF
3$2,311,031,117$2,267,966,589.88$8,336$1,066.78+$2311.02MEFRMF
4$124,181,822,284$121,709,018,988.28$8,437$1,384.80+$124181.81MEFRMF
5$6,244,985,365,552$6,112,110,815,708.32$9,013$1,875.40+$6244985.36MEFRMF
6$293,945,892,838,957$287,263,758,497,816.90$10,306$2,680.72+$293945892.83MEFRMF
7$12,951,203,390,243,552$12,636,681,284,905,868.00$12,820$4,101.38+$12951203390.23MEFRMF
8$534,203,501,715,883,900$520,345,714,088,323,260.00$17,673$6,826.70+$534203501715.87MEFRMF
9$20,630,391,404,201,763,000$20,058,793,657,365,766,000.00$27,543$12,591.86+$20630391404201.73MEFRMF
10$746,046,519,283,998,900,000$723,972,000,481,503,000,000.00$49,560$26,258.71+$746046519283998.88MEFRMF

EFRMF vs PFE: Complete Analysis 2026

EFRMFStock

East Africa Metals Inc., a mineral exploration company, focuses on the identification, acquisition, exploration, development, and sale of base and precious mineral resource properties in the Federal Democratic Republic of Ethiopia and the United Republic of Tanzania. The company primarily explores for gold, copper, silver, and zinc deposits. Its principal assets and interests include a 70% interest in the Harvest property, as well as 100% interest in the Adyabo project that comprises two exploration licenses covering 195 square kilometers situated in the Arabian Nubian Shield in northern Ethiopia; and an interest in the Handeni property comprising two mining licenses covering 9.9 square kilometers, and contiguous mineral tenures totaling approximately 83.5 square kilometers located in northeastern Tanzania. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Full EFRMF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this EFRMF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFRMF vs SCHDEFRMF vs JEPIEFRMF vs OEFRMF vs KOEFRMF vs MAINEFRMF vs JNJEFRMF vs MRKEFRMF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.